Skip to content

Inspection Record

HEC Pharm Co. Ltd. — FDA 483 Findings

US FDAInspected 2025-11-21Published 2026-10-20 5 findingsEquipment and facilityOther quality systemEnvironmental monitoringValidation and qualificationLaboratory and QC controls

Inspectors Adetutu M GidadoThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Manufacturing equipment are not maintained to prevent malfunctions.

2Other quality system

Analytical method used for determination of impurities in API is inadequately validated.

3Environmental monitoring

The culture media ®@® used for microbial enumeration and environmental monitoring is not validated or adequately validated to determine its capability to support the growth of specific microorganisms.

4Validation and qualification

Manufacturing computer and or related system is not adequately qualified for their intended use.

5Laboratory and QC controls

Laboratory instruments are inadequately qualified for their intended use.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

HEC Pharm Co. Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.